2023
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance
Sridhar S, Powles T, Climent Durán M, Park S, Massari F, Thiery-Vuillemin A, Valderrama B, Ullén A, Tsuchiya N, Aragon-Ching J, Gupta S, Petrylak D, Bellmunt J, Wang J, Laliberte R, di Pietro A, Costa N, Grivas P, Sternberg C, Loriot Y. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance. European Urology 2023, 85: 154-163. PMID: 37714742, DOI: 10.1016/j.eururo.2023.08.001.Peer-Reviewed Original ResearchBest supportive careProgression-free survivalAdvanced urothelial carcinomaFirst-line chemotherapyPlatinum-based chemotherapyOverall survivalFirst-line maintenanceChemotherapy durationMaintenance treatmentUrothelial carcinomaFirst-line platinum-based chemotherapyAnalysis of OSAdvanced urothelial cancerPhase 3 trialAnalysis of subgroupsAdvanced UCPrior chemotherapyProspective trialSafety findingsSupportive careHazard ratioUrothelial cancerDisease progressionChemotherapyOverall population
2022
1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study
De Wit R, Vaughn D, Fradet Y, Fong L, Vogelzang N, Duran M, Necchi A, Petrylak D, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Bajorin D, Choueiri T, Xu J, Imai K, Moreno B, Bellmunt J, Lee J. 1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study. Annals Of Oncology 2022, 33: s1336-s1337. DOI: 10.1016/j.annonc.2022.07.1825.Peer-Reviewed Original ResearchCell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.
Lu Y, Plets M, Morrison G, Cunha A, Cen S, Rhie S, Siegmund K, Daneshmand S, Quinn D, Meeks J, Lerner S, Petrylak D, McConkey D, Flaig T, Thompson I, Goldkorn A. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Journal Of Clinical Oncology 2022, 40: 4506-4506. DOI: 10.1200/jco.2022.40.16_suppl.4506.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyBladder cancer patientsPathologic responseTreatment responseCell-free DNA methylationCancer patientsMuscle-invasive bladder cancer patientsMuscle-invasive bladder cancerCycles of chemotherapyStandard neoadjuvant chemotherapyCooperative group trialsStandard of careProspective cooperative group trialsIndependent predictive abilityRadical cystectomyPredictive biomarkersPathologic respondersBladder cancerGroup trialsMR scoreBlood samplesChemotherapyPatientsPlasma samplesResponse scores
2021
698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
Rosenberg J, Powles T, Sonpavde G, Loriot Y, Duran I, Lee J, Matsubara N, Vulsteke C, Castellano D, Mamtani R, Sridhar S, Pappot H, Gurney H, Bedke J, van der Heijden M, Campbell M, Wu C, Matsangou M, Petrylak D. 698P Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma. Annals Of Oncology 2021, 32: s710-s711. DOI: 10.1016/j.annonc.2021.08.094.Peer-Reviewed Original Research579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Petrylak D, Perez-Gracia J, Lacombe L, Bastos D, Mahammedi H, Kwan E, Zschäbitz S, Armstrong A, Pachynski R, Goh J, Burotto M, Gravis G, McCune S, Limón J, Retz M, Saad F, Amin N, Li J, Unsal-Kacmaz K, Fizazi K. 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). Annals Of Oncology 2021, 32: s629-s630. DOI: 10.1016/j.annonc.2021.08.1092.Peer-Reviewed Original Research
2020
A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)
Powles T, van der Heijden M, Gauna D, Loriot Y, Galsky M, Petrylak D, Ogawa O, Park S, Necchi A, Lee J, De Giorgi U, Bögemann M, Bamias A, Fay A, Duran I, Angra N, Gupta A, He P, Levin W, Bellmunt J. A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE). Annals Of Oncology 2020, 31: s550-s551. DOI: 10.1016/j.annonc.2020.08.769.Peer-Reviewed Original Research
2019
PT126 A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. PT126 A phase 3 study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC): EV-301, a trial-in-progress. European Urology Open Science 2019, 18: e1836-e1837. DOI: 10.1016/s1569-9056(19)31330-2.Peer-Reviewed Original ResearchMature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
Rosenberg J, Sridhar S, Zhang J, Smith D, Ruether J, Flaig T, Baranda J, Lang J, Plimack E, Sangha R, Heath E, Merchan J, Quinn D, Srinivas S, Milowsky M, Wu C, Gartner E, Melhem-Bertrandt A, Petrylak D. Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2019, 37: 377-377. DOI: 10.1200/jco.2019.37.7_suppl.377.Peer-Reviewed Original ResearchMetastatic urothelial cancerTreatment-related AEsLiver metastasesMedian followUrothelial cancerPrimary tumor siteUnmet medical needMedian PFSPrior chemotherapyMonotherapy studiesMedian durationPoor prognosisCombination therapyPlatinum chemotherapyMature resultsDay 1Nectin-4Medical needTumor siteSecondary objectivePhase IAntitumor activityEncouraging responseSurvival dataChemotherapyLong-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC).
Balar A, Dreicer R, Loriot Y, Perez-Gracia J, Hoffman-Censits J, Petrylak D, Van Der Heijden M, Shen X, Ding B, Ramirez-Montagut T, Rosenberg J. Long-term outcomes in elderly patients (pts) from IMvigor210: Atezolizumab (atezo) in metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2019, 37: 394-394. DOI: 10.1200/jco.2019.37.7_suppl.394.Peer-Reviewed Original ResearchMetastatic urothelial cancerElderly ptsCR ratePD-L1 statusSingle-arm studyLong-term outcomesLong-term efficacyEvaluable ptsMedian OSEfficacy outcomesElderly patientsClinical outcomesUrothelial cancerClinical benefitPoor outcomeSubgroup analysisOverall populationChemotherapyOutcomesCisplatinAtezoAtezolizumabQ3wOSPatients
2018
901P Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045
Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Necchi A, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Jensen E, Frenkl T, Perini R, Bajorin D. 901P Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator’s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals Of Oncology 2018, 29: viii320-viii321. DOI: 10.1093/annonc/mdy283.110.Peer-Reviewed Original Research922TiP EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)
Petrylak D, Rosenberg J, Duran I, Loriot Y, Sonpavde G, Wu C, Gartner E, Melhem-Bertrandt A, Powles T. 922TiP EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC). Annals Of Oncology 2018, 29: viii328. DOI: 10.1093/annonc/mdy283.131.Peer-Reviewed Original Research930TiP Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression
Sternberg C, Bellmunt J, Nishiyama H, Petrylak D, Quinn D, Nakajima K, Lu C, Holynskyj A. 930TiP Phase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression. Annals Of Oncology 2018, 29: viii331. DOI: 10.1093/annonc/mdy283.139.Peer-Reviewed Original Research
2017
3LBA Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study
Necchi A, Bellmunt J, De Wit R, Vaughn D, Fradet Y, Lee J, Fong L, Vogelzang N, Climent M, Petrylak D, Choueiri T, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Mai Y, Puhlmann M, Perini R, Bajorin D. 3LBA Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study. European Journal Of Cancer 2017, 72: s2. DOI: 10.1016/s0959-8049(17)30092-8.Peer-Reviewed Original Research
2016
285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
Park S, Castellano D, Petrylak D, Galsky M, van der Heijden M, Loriot Y, Ogawa O, Su W, Huang W, Levin W, Ferro S, Ben Y, Bellmunt J, Powles T. 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) ± tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC). Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw583.011.Peer-Reviewed Original Research285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) 6 tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC)
Park S, Castellano D, Petrylak D, Galsky M, van der Heijden M, Loriot Y, Ogawa O, Su W, Huang W, Levin W, Ferro S, Ben Y, Bellmunt J, Powles T. 285TiP DANUBE: A Phase 3 randomised study of first-line durvalumab (MEDI4736) 6 tremelimumab vs standard of care (SoC) chemotherapy (CT) in patients (pts) with Stage IV urothelial carcinoma (UC). Annals Of Oncology 2016, 27: ix88-ix89. DOI: 10.1016/s0923-7534(21)00442-7.Peer-Reviewed Original Research842TiP A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Powles T, Grivas P, Aragon-Ching J, Faroun Y, Kessler E, Tomita Y, Chakrabarti D, Laliberte R, Shnaidman M, Petrylak D. 842TiP A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals Of Oncology 2016, 27: vi292. DOI: 10.1093/annonc/mdw373.69.Peer-Reviewed Original ResearchA phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE.
Powles T, Galsky M, Castellano D, Van Der Heijden M, Petrylak D, Armstrong J, Belli R, Ferro S, Ben Y, Bellmunt J. A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE. Journal Of Clinical Oncology 2016, 34: tps4574-tps4574. DOI: 10.1200/jco.2016.34.15_suppl.tps4574.Peer-Reviewed Original Research
2010
1706 CARBOPLATIN VS. CISPLATIN-BASED CHEMOTHERAPY IN THE PERIOPERATIVE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER
Wosnitzer M, Hruby G, Cordon-Cardo C, Benson M, Petrylak D, McKiernan J. 1706 CARBOPLATIN VS. CISPLATIN-BASED CHEMOTHERAPY IN THE PERIOPERATIVE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER. Journal Of Urology 2010, 183: e658-e659. DOI: 10.1016/j.juro.2010.02.1553.Peer-Reviewed Original Research
2006
Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT
Chan J, Ryan C, Venner P, Petrylak D, Chatta G, Ruether J, Chi K, Young J, Shen C, Beer T. Skeletal related events (SREs) in metastatic androgen independent prostate cancer (AIPC) treated with docetaxel-based chemotherapy: Results from ASCENT. Journal Of Clinical Oncology 2006, 24: 4614-4614. DOI: 10.1200/jco.2006.24.18_suppl.4614.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerSkeletal related eventsSRE-free survivalMetastatic androgen-independent prostate cancerDocetaxel-based chemotherapyZoledronic acidDN-101SRE incidenceZA useRisk of SREsDocetaxel-based therapySpinal cord compressionRandomized clinical trialsIndependent prostate cancerAIPC patientsCord compressionProlong survivalProspective studyClinical trialsModern chemotherapyProstate cancerPatientsCochran-MantelChemotherapyEntire group
2005
Chemotherapy agents and timing of chemotherapy in prostate cancer management
Donohue K, Petrylak D. Chemotherapy agents and timing of chemotherapy in prostate cancer management. Current Prostate Reports 2005, 3: 58-61. DOI: 10.1007/s11918-005-0017-1.Peer-Reviewed Original ResearchHormone-refractory prostate cancerSurvival benefitProstate cancerMetastatic hormone-refractory prostate cancerProstate-specific antigen levelTiming of chemotherapyPhase 2 trialProstate cancer managementMedian survivalPalliative benefitSurvival improvementAntigen levelsClinical trialsChemotherapy agentsCancer managementSingle agentChemotherapeutic agentsDocetaxelTrialsPhase 3Preliminary dataChemotherapyEstramustinePatientsCancer